Bio-Path Q1 net loss $5.3M ($0.66/share); cash burns to $6.7M; clinical milestones Q2/3

BIO-PATH HOLDINGS, INC.

2023-Q1 EPS reported -$0.66

Net loss $5.3M ($0.66/share) vs $3.4M ($0.47) Q1 2022; R&D spend doubled to $4.0M.
Cash $6.7M at Mar 31, down from $10.4M Dec 31; net cash used in ops $3.7M.
BP1001-A solid tumor trial initial cohort completion/data readout expected mid-2023.
BP1002 relapsed/refractory AML cohort readout expected mid-2023.
Prexigebersen Phase 2 AML: two cohorts exceeded min efficacy for expansion; interim analyses start Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2022 results: net income a net loss of $3.4 million, or $0.47 per share.

Period: first quarter ended March 31, 2022
Net income: a net loss of $3.4 million, or $0.47 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2023 results: net income a net loss of $5.3 million, or $0.66 per share.

Period: first quarter ended March 31, 2023
Net income: a net loss of $5.3 million, or $0.66 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $5.3 million, or $0.66 per share, for the three months ended March 31, 2023, compared to a net loss of $3.4 million, or $0.47 per share, for the three months ended March 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-009499

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.